Technology
Explore technologies transforming drug discovery and development, including artificial intelligence, automation, genomics, bioinformatics, imaging, robotics, advanced laboratory platforms and computational tools that accelerate target identification, therapeutic innovation and translational research.
Webinars and whitepapers
- Previous
- Next
Technology
ArticleStrong binding isn’t enough – why cellular target engagement matters
Promising compounds don’t always engage their targets in living cells. At ELRIG Drug Discovery 2026, Dr Joshua Sopp of Promega discusses why earlier cellular testing matters and how BRETSA could help researchers investigate new drug targets.
ReportLab Automation 2026: Inside the labs making drug discovery faster and more reliable
Six scientists and industry experts discuss the challenges of automating drug discovery, from improving screening reliability and reproducibility to developing more autonomous laboratories.
ArticleHow AI is changing the way therapeutic antibodies are designed
What if researchers could design therapeutic antibodies instead of relying on screening millions of candidates? Generative AI is making this increasingly possible, offering new ways to tackle challenging targets.
ArticleVirtual cells vs experimental models: which can you trust?
How reliable are AI virtual cells compared with experimental models? We examine what each can predict or measure, the evidence behind their reliability and their role in early drug discovery.
Join now
Unlock exclusive industry insights
- Bookmark articles and resources to access anytime
- Enjoy free access to industry leading resources, webinars and insights
- Stay informed with the latest news and breakthroughs
- Receive updates and recommendations tailored to your research interests
InterviewHow multiomics can strengthen drug target discovery
How can multiomics help researchers identify more promising drug targets? Dr Shi-qi An explores how combining molecular data can reveal therapeutic vulnerabilities and mechanisms of drug resistance.
ArticleThe next gene-editing breakthrough may start with the donor template
The editing machinery gets much of the attention in genome editing, but it’s the donor DNA template that can determine whether an edit works. Long synthetic ssDNA could offer researchers another option.
ArticleScientists are already using AI agents. Most of what they learn goes unpublished.
Dr Raminderpal Singh speaks to Dr Srijit Seal about how AI agents are changing computational drug discovery, the impact on scientists’ daily work and why valuable findings remain unpublished.
ArticleWhat will it take to trust human-relevant models in drug discovery?
Could organ-on-a-chip technology help identify drug failures before clinical trials? Jim Corbett of Emulate discusses the evidence needed to make human-relevant models reliable tools in drug discovery.
ArticleEarlier MSA detection could guide alpha-synuclein drug discovery
MSA and Parkinson’s share the same protein pathology, yet MSA progresses far faster. Could earlier detection reveal why and help researchers identify more effective targets for drug discovery?
ArticleReproducible organoids start with reliable cytokines
The right signals can make or break an organoid model. From growth and differentiation to downstream drug testing, cytokines and growth factors are critical to creating cultures researchers can rely on.
ArticleFinding drug targets through the noise of complex disease
The strongest disease signal may not point to the best drug target. AI could help researchers identify what matters within complex biological networks.
ArticleFaster, scalable biologics stability testing without sacrificing data quality
Stability problems can derail promising biologics late in development. Bringing high-throughput testing earlier into discovery could help researchers identify risks before they become costly failures.
InterviewA sceptical guide to AI agents in drug discovery
AI agents promise to transform drug discovery, but where do they really add value? Dr Eric Ma examines search, model choice, vendor lock-in and why scientific expertise matters more than ever.
ArticleDrug discovery in Q3 2026 – what changed and why it matters
Agentic AI, ultralarge virtual screening, molecular glues and human-relevant models were among the key developments in early drug discovery during Q3 2026. Drug Target Review examines what changed, why it matters and what to watch heading into Q4.
ArticleAI agents vs scientists: what should we automate in drug discovery?
AI agents can search, analyse and plan across drug discovery workflows, but where should scientists hand over control? We examine what to automate, what to check and where human judgement matters most.
ArticleHow disease exposes hidden epitopes that AI models may miss
A protein can look very different in disease without a single change to its sequence. Measuring these structural changes could reveal drug targets invisible to genomic and expression data alone.
ArticleHow protective gene variants are revealing new drug targets
Finding the right drug target remains one of discovery’s biggest challenges. Human genetics is helping researchers strengthen the evidence before committing years of research and investment.
ArticleWhy AI struggles with new drug targets – and how physics could help
Virtual screening can assess billions of compounds, but performance can fall on unfamiliar targets. Combining AI with molecular physics could help make predictions more reliable.
ArticleTurning CNS biomarkers into better drug development decisions
Why do promising CNS therapies struggle to translate into patients? Three experts explore how biomarkers can track therapeutic effects, improve patient selection and guide development decisions.